Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRX4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,591.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injector units. The contract is structured as a firm fixed-price delivery order with no set-aside designation, reflecting the contractor's competitive capabilities in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499,999,999 through December 31, 2036.
The PPV-G GEN V represents a comprehensive $30.3 billion acquisition strategy through which the Defense Logistics Agency establishes regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial performance capability across the Defense Logistics Agency's Medical Supply Chain division, delivering diverse pharmaceutical products including branded and generic medications, biologics, vaccines, and specialty pharmaceuticals. The delivery order is scheduled for completion by February 5, 2026, with performance to occur at the contractor's Park Ridge, Illinois location, supporting the military healthcare system's recurring pharmaceutical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FCRX4?
SPE2DR26FCRX4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FCRX4 worth?
The government has obligated $11,591 on SPE2DR26FCRX4.
Is contract SPE2DR26FCRX4 an order under another contract?
Yes. SPE2DR26FCRX4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRX4 competed?
The extent of competition for SPE2DR26FCRX4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award